Surrozen Announces Pricing of $60 Million Underwritten Offering of Common Stock
Guggenheim keeps this U.S. biotech stock as its top pick
Guggenheim Maintains Buy on Surrozen, Raises Price Target to $80
Cantor Fitzgerald Maintains Overweight on Surrozen, Raises Price Target to $62
Surrozen Reports Third Quarter 2026 Financial Results and Provides Business Update
Surrozen: The Wnt Science Is Compelling, But The Stock Prices In Too Much Success
Surrozen to Present at Upcoming Healthcare Investor Conference
Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million
Top Biotech Stock: Guggenheim Names Surrozen as Best Pick
Surrozen secures FDA clearance for SZN-8141 clinical trial
Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
HC Wainwright & Co. Maintains Buy on Surrozen, Raises Price Target to $54
Surrozen Gains Momentum as FDA Submission Opens Path for Lead Therapy
Surrozen, Inc. (SRZN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Surrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
Surrozen Submits IND Application To FDA Seeking To Evaluate SZN-8141, Bifunctional Wnt Agonist And Vascular Endothelial Growth Factor Antagonist Antibody, For Treatment Of Diabetic Macular Edema
Surrozen to Present at Upcoming Healthcare Investor Conferences
HC Wainwright & Co. Reiterates Buy on Surrozen, Maintains $44 Price Target
Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update
Surrozen Highlights Wnt Retina Pipeline, SZN-8141 IND Timeline at H.C. Wainwright
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.